**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 20911**

**Manuscript Type: Review**

**Mechanisms of intrahepatic triglyceride accumulation**

Ress C *et al*. Pathophysiology of hepatic steatosis

Claudia Ress, Susanne Kaser

**Claudia Ress, Susanne Kaser,** Department of Internal Medicine I, Medical University Innsbruck, 6020 Innsbruck, Austria

**Claudia Ress, Susanne Kaser,** Christian Doppler Laboratory of Metabolic Crosstalk, Department of Internal Medicine 1, Medical University Innsbruck, 6020 Innsbruck, Austria

**Author contributions:** Ress C and Kaser S both contributed to conception, drafting, revising and final approval of the manuscript.

**Supported by** Austrian Federal Ministry of Science, Research and Economy and the National Foundation for Research, Technology and Development is gratefully acknowledged.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Susanne Kaser, MD,** Christian Doppler Laboratory of Metabolic Crosstalk, Department of Internal Medicine 1, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. susanne.kaser@i-med.ac.at

**Telephone:** +43-5125040

**Fax:** +43-512-50428539

**Received:** June 25, 2015

**Peer-review started:** June 27, 2015

**First decision:** July 20, 2015

**Revised:** August 20, 2015

**Accepted:** September 28, 2015

**Article in press:**

**Published online:**

**Abstract**

Hepatic steatosis defined as lipid accumulation in hepatocytes is very frequently found in adults and obese adolescents in the Western World. Etiologically, obesity and associated insulin resistance or excess alcohol intake are the most frequent causes of hepatic steatosis. However, steatosis also often occurs with chronic hepatitis C virus (HCV) infection and is also found in rare but potentially life-threatening liver diseases of pregnancy. Clinical significance and outcome of hepatic triglyceride accumulation is highly dependent on etiology and histological pattern of steatosis. This review summarizes current concepts of pathophysiology of common causes of hepatic steatosis including non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), chronic HCV infections, drug induced forms of hepatic steatosis and acute fatty liver of pregnancy (AFLP). Concerning pathophysiology of NAFLD this work is focused on the close correlation between insulin resistance and hepatic triglyceride accumulation highlighting the potential harmful effects of systemic insulin resistance on hepatic metabolism of fatty acids on the one side and the role of lipid intermediates on insulin signalling on the other side. Current studies on lipid droplet morphogenesis have identified novel candidate proteins and enzymes in NAFLD.

**Key words:** Steatosis; Lipid accumulation; Fatty acids; Insulin resistance; Triglycerides

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Fatty liver disease is a highly prevalent state in the Western World. This article summarises the most frequent causes and states of hepatic steatosis including non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver, drug-induced forms, hepatitis C virus infections and acute fatty liver of pregnancy. Important pathophysiological and cellular aspects of various forms of fatty liver disease are reviewed as well as the clinically relevant close interaction between hepatic triglyceride accumulation and insulin resistance in NAFLD.

Ress C, Kaser S. Mechanisms of intrahepatic triglyceride accumulation. *World J Gastroenterol* 2015; In press

**Introduction**

Hepatic steatosis is defined by the accumulation of triglycerides resulting in more than 5% of hepatocytes containing visible lipid droplets in either a micro- or macrovesicular pattern. Most frequently, steatosis is histologically assessed by using a classification that was originally suggested for grading of non-alcoholic fatty liver disease (NAFLD) by Javor *et al*[[1](#_ENREF_1)]: grade 0: < 5% hepatocytes involved; grade 1: 5%-33% hepatocytes involved; grade 2: > 33%-66% hepatocytes involved, grade 3: > 66% hepatocytes involved. At the cellular level steatosis is a dysbalance of hepatic fatty acid uptake, lipogenesis, β-oxidation and triglyceride export in VLDL particles.

Fatty liver might be caused by several conditions, diseases or drugs, however, obesity, insulin resistance and dyslipidemia as well as excess alcohol intake are the most frequent ones causing NAFLD or alcoholic fatty liver disease (AFLD). Beyond metabolic or alimentary causes, fatty liver can also be found in patients with hepatitis C virus (HCV) infection and rarely in pregnancy. Other rare causes of fatty liver disease are summarized in Table 1[[2](#_ENREF_2)]. This review will focus on the most frequent and important causes of fatty liver disease.

The natural course of fatty liver is strongly dependent on etiology and comorbidities. For example, in NAFLD 20-30% of patients with steatosis will develop non-alcoholic steatohepatitis (NASH) which is associated with increased total and cardiovascular mortality [[3](#_ENREF_3)]. NASH is complicated by liver cirrhosis in 2-5% of patients [[2](#_ENREF_2)]. Co-occurrence of steatosis and chronic HCV infection has been found to be associated with poorer outcome when compared to patients without steatosis [[4](#_ENREF_4)].

**NAFLD**

NAFLD has become the most common cause of elevated liver enzymes in Western World affecting 30%-40% of men and 15%-20% of women in the general population[[5](#_ENREF_5)] and up to 70% of type 2 diabetics[[6](#_ENREF_6)]. It is now considered the hepatic manifestation of the metabolic syndrome which comprises a spectrum of metabolic disorders including overweight or obesity, insulin resistance, dyslipidemia and hypertension[[7](#_ENREF_7),[8](#_ENREF_8)]. According to estimates NAFLD will become the most frequent indication for liver transplantation by 2030[[9](#_ENREF_9)]. Beyond excess mortality rate from advanced liver disease NAFLD is associated with significantly increased cardiovascular risk mostly due to associated disturbances in glucose and lipid metabolism[[9](#_ENREF_9)].

Intracellular lipid accumulation in NAFLD results from an imbalance between hepatic fatty acid uptake, lipid synthesis, lipid oxidation and export *via* VLDL particles. Several studies have stressed the importance of adipose tissue lipolysis in development of hepatic steatosis. Increased total fat mass in obesity is associated with elevated whole body lipolysis[[10](#_ENREF_10),[11](#_ENREF_11)] and excess fatty acid uptake into the liver. Further highlighting the role of adipose tissue in triglyceride metabolism, Nye and colleagues[[12](#_ENREF_12)] found that glycerol 3-phosphate which is essential for triglyceride synthesis primarily originates from glyceroneogenesis and only to a lesser extent from glycolysis. Accordingly, mice lacking fatty acid transporter protein 5 (FATP 5), which is the primary fatty acid transporter in the liver, are protected from diet-induced steatosis[[13](#_ENREF_13)]. Underlining the importance of the adipose tissue in development of NAFLD, lipodystrophic patients who lack visceral and peripheral fat accumulation due to leptin deficiency display severe hepatic steatosis and insulin resistance[[14](#_ENREF_14),[15](#_ENREF_15)]. Similarly, subjects with mutations of perilipin-1 - an inhibitor of adipose triglyceride lipase (ATGL) and stabilizer of lipid droplets in adipose tissue – have also profound hepatic steatosis and insulin resistance[[16](#_ENREF_16)].

In addition to increased influx of fatty acids and their esterification, de novo lipogenesis (DNL), which from a quantitative point of view only play a minor role in hepatic lipid accumulation, is also increased in NAFLD: In affected patients DNL is significantly increased when compared to healthy controls[[17-19](#_ENREF_17)]. Increased levels of ligand-activated transcription factor α (LXR α) and sterol regulating element binding protein 1c (SREBP-1c) have been described as major contributors to increased DNL in NAFLD[[20](#_ENREF_20),[21](#_ENREF_21)]. Further highlighting the close connection between glucose and fatty acid metabolism high glucose levels induce pyruvate production *via* stimulation of carbohydrate response element binding protein (ChREBP). Pyruvate is the principle source of acetyl-CoA in fatty acid synthesis[[22](#_ENREF_22)]. Very recently, Perry and colleagues[[23](#_ENREF_23)] found that white adipose tissue - derived hepatic acetyl-CoA is the critical determinant of insulin-induced suppression of hepatic glucose production. By decreasing oxidation of fatty acids on the one side and inducing DNL on the other side, fructose consumption is a well-known highly effective driver of hepatic steatosis[[24](#_ENREF_24),[25](#_ENREF_25)].

DNL is closely related to β-oxidation *via* SREBP-1c: Besides induction of lipogenic enzymes, SREBP-1c also activates acetyl-CoA carboxylase 2 (ACC2) resulting in increased levels of malonyl-CoA which decreases β-oxidation *via* diminishing shuttling of fatty acids into the mitochondrium by inhibiting carnitine palmitoyl transferase 1 (CPT-1). AMP activated protein kinase (AMPK) is also a key regulator of intracellular lipid metabolism: By sensing cellular AMP levels activation of AMPK stimulates fatty acid β -oxidation and inhibits ATP-consuming processes such as DNL[[26](#_ENREF_26)]. Mitochondrial dysfunction and resulting impaired fatty acid oxidation have been suggested to significantly contribute to pathogenesis of NAFLD[[27](#_ENREF_27),[28](#_ENREF_28)].

On a cellular level, triglycerides are stored in lipid droplets (LD) which supply fatty acids for oxidation and VLDL secretion. As described in detail in a very recent review by Mashek and colleagues[[29](#_ENREF_29)], LDs are formed within the lipid bilayer of the endoplasmatic reticulum (ER) and subsequently budded. Latter process requires action of certain fat storage - inducible transmembrane proteins as well as seipin[[30](#_ENREF_30)]. Growth of LDs is dependent on triglyceride and phospholipid synthetic enzymes which are present on the LD surface. LDs are catabolized *via* 3 different mechanisms: Adipose triglyceride lipase (ATGL)/patatin-like phospholipase domain-containing protein 2 (PNPLA2) catalyzes the first step of triglyceride hydrolysis and partitions hydrolyzed fatty acids to β -oxidation[[31](#_ENREF_31)]. Activity of ATGL is strongly influenced by LD - associated proteins such as perilipins 2 and 5[[32](#_ENREF_32)]. Sirtuin 1 has been shown to also regulate ATGL activity probably *via* peroxisome proliferator-activated receptor α (PPARα) [33](#_ENREF_33)]. LDs are also degraded by lysosomal lipases, a process that is determined by the small guanosine triphosphatase RAB7[[34](#_ENREF_34),[35](#_ENREF_35)]. The third way of LD catabolism is mediated by carboxylesterase 3 and cell death inducing DFF45-like effector B (CIDEB) which are involved in repacking of cytosolic LDs in the ER leading to synthesis of VLDL particles[[36](#_ENREF_36),[37](#_ENREF_37)]. Increased expression of LD associated proteins such as 17 β hydroxysteroid dehydrogenase 13 and perilipins 1,2,3 and 5 have been reported in NAFLD[[38-42](#_ENREF_38)]. Patatin-like phospholipase domain-containing protein 3 (PNPLA3) polymorphisms have been identified as the strongest genetic factor associated with NAFLD[[43](#_ENREF_43)].

Apolipoprotein A5 is a protein with extra- and intracellular effects on lipid metabolism[[44](#_ENREF_44)]. In obese subjects undergoing bariatric surgery improvements of hepatic steatosis were associated with decreased hepatic apoA5 expression. Direct involvement of apolipoprotein A5 in hepatic triglyceride accumulation has been shown in a hepatic cell culture model[[45](#_ENREF_45)]. In adipocytes, apolipoprotein A5 has been found to surround lipid droplets[[46](#_ENREF_46)] suggesting a potential role of apolipoprotein A5 in hepatic lipid droplet metabolism.

Stressing the metabolic consequences of steatosis, hepatic triglyceride accumulation is associated with increased gluconeogenesis, decreased glycogen synthesis and inhibition of insulin signalling[[47](#_ENREF_47),[48](#_ENREF_48)] as well as alterations in hepatokine productions[[49](#_ENREF_49)]. Lipid intermediates of long-chain fatty acids (LCAF) have a crucial role in hepatic insulin resistance in NAFLD. In hepatocytes, LCAF are esterified with glycerol-3-phosphate to form monoacylglycerol, diacylglycerol (DAG) and triacylglycerol in a finally[[9](#_ENREF_9)]. Hepatic DAG content has been positively correlated with inhibition of insulin signalling in mice and humans with NAFLD[[48](#_ENREF_48),[50](#_ENREF_50),[51](#_ENREF_51)]. Mechanistically, DAG induce increased translocation of protein kinase C ε (PKCε) to the plasma membrane where it binds and inhibits the activity of the intracellular kinase domain of the insulin receptor resulting in diminished activation of the canonical insulin pathway[[52](#_ENREF_52),[53](#_ENREF_53)]. As a consequence activation of glycogen synthesis and inhibition of gluconeogenesis is reduced[[48](#_ENREF_48)]. Unesterified lipid intermediates also exert proinflammatory properties by inducing ER stress which leads to the activation of c-Jun N-terminal kinases and NFκB resulting in decreased phosphorylation of insulin receptor substrate-2 (IRS-2)[[9](#_ENREF_9),[54](#_ENREF_54),[55](#_ENREF_55)]. Accumulation of ceramides in the plasma membrane have also been found to alle*via*te insulin signalling[[56](#_ENREF_56)]. Pathophysiological aspects of NAFLD are summarized in Figure 1.

**AFLD**

Chronic alcohol exposure is another frequent cause of fatty liver disease. More than 90% of alcoholics have fatty liver disease which however potentially resolves by abstinence from alcohol[[57-59](#_ENREF_57)]. Chronic consumption of more than 30 g of pure alcohol was demonstrated to significantly increase the risk of chronic liver disease[[60](#_ENREF_60)]. Susceptibility factors include female sex, obesity, cigarette smoking as well as coexistence of other hepatic disorders such as hepatitis B or C virus infection, non-alcoholic fatty liver disease or hemochromatosis[[61](#_ENREF_61)].

Alcohol is metabolized *via* two main pathways in the liver, the oxidative pathway which is mediated by the alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) as well as the non-oxidative cytochrome P450 2E1 pathway[[62-64](#_ENREF_62)].

Ethanol is converted by the cytosolic enzyme ADH to acetaldehyde and further metabolized to acetate by the mitochondrial enzyme ALDH. The reactions are both coupled to the reduction of NAD to NADH[[65](#_ENREF_65),[66](#_ENREF_66)].

Excess NADH has deleterious effects on gluconeogenesis and fatty acid synthesis[[67](#_ENREF_67)] Furthermore acetaldehyde was found to induce lipogenesis by increasing SREBP-1c expression[[68](#_ENREF_68)]. Increased fatty acid synthesis leads to the accumulation of fatty acid intermediates such as malonyl-CoA which suppresses fatty acid transport into the mitochondria and their oxidation by CPT-1[[69](#_ENREF_69)]. Alcohol mainly *via* its metabolite acetaldehyde further inhibits PPARα, which is the main transcription factor for genes involved in oxidation, transport and export of fatty acids[[70-74](#_ENREF_70)]. In PPARα deficient mice chronic ethanol feeding was associated with progressive intrahepatic triglyceride accumulation due to reduced β-oxidation and alterations in tricarboxylic acid cycle and the electron transfer chain[[75](#_ENREF_75)]. In a mouse model, alcohol feeding resulted in dysfunction of ALDH2 and aldehyde accumulation. Pharmacological activation of ALDH2 reversed alcoholic steatosis in these mice underlining the deleterious effects of accumulating metabolic products of alcohol[[76](#_ENREF_76)]. In a very recent work Guo *et al*[[77](#_ENREF_77)] reported that ALDH2´s beneficial role on hepatic steatosis and inflammation might be mediated through regulation of autophagy.

Ceramide induced inhibition of AMPK and impaired hepatic adiponectin effects might further contribute to increased fatty acid synthesis and reduced fatty acid oxidation[[78-80](#_ENREF_78)]. Besides β-oxidation and lipogenesis VLDL export is also affected by alcohol: triglyceride export is impaired due to suppression of phosphatidylcholine, acetaldehyde induced inhibition of microtubular assembly and reduced apolipoprotein synthesis[[81](#_ENREF_81)]. The role of perilipin 2 which is a major LD protein was recently demonstrated in perilipin-deficient mice which are protected from ethanol-induced hepatic steatosis[[82](#_ENREF_82)]. Several studies suggest that lipin-1, which is critically involved in triglyceride synthesis might have a significant role in alcoholic liver disease. Liver-specific deficiency of lipin 1 was associated with increased hepatic triglyceride and cholesterol accumulation and inflammation in ethanol fed mice[[83](#_ENREF_83)]. Sirtuin (SIRT1) which is downregulated in mice models of alcoholic liver disease was found to affect hepatic steatosis, inflammation and fibrosis *via* lipin-1[[84](#_ENREF_84)].

**Chronic HCV infection**

Steatosis is also found in up to 80% of patients with chronic HCV infection[[85](#_ENREF_85)]. Co-occurrence of steatosis and chronic HCV infection are associated with progression of liver disease and poor response in Interferon-α based treatment[[4](#_ENREF_4),[86-89](#_ENREF_86)]. Prevalence of steatosis in chronic HCV infection is double than that found in patients with hepatitis B virus infection suggesting that co-occurrence of NAFLD and HCV does not fully explain high prevalence of steatosis in patients with chronic HCV infection[[85](#_ENREF_85),[90](#_ENREF_90)]. Additionally, probability of steatosis is significantly higher in genotype 3 than in non-3 genotype HCV infections which argues in favour of viral induction of fatty liver in genotype 3 HCV infection[[4](#_ENREF_4)]. Accordingly, fatty liver was found to be associated with HCV RNA levels in genotype 3a and BMI in genotype 1 HCV infection[[91](#_ENREF_91)]. Interestingly, infection of immortalized hepatoma cell line HepG2 with HCV genotype 1b was associated with suppressor of cytokine signalling 3 (SOCS-3) mediated impairment of insulin signalling when compared to HCV genotype 2 infected cells[[92](#_ENREF_92)]. All HCV genotype but genotype 3 to a higher extend exert direct effects on hepatic lipid metabolism resulting in occurrence of large droplets in hepatocytes[[85](#_ENREF_85),[93](#_ENREF_93)]. HCV makes use of VLDL assembly and secretion pathways in production of infectious virus. In virion morphogenesis, LDs are targeted by virus-encoded proteins. LDs have also been shown to influence the course of the infection. The role of LDs in HCV infection has recently been reviewed extensively by Filipe A *et al*[[93](#_ENREF_93)]. Increased intracellular triglyceride accumulation in HCV infection might be due to both direct viral effects and indirectly resulting from accompanying insulin resistance[[93-105](#_ENREF_93)]. Decreased β-oxidation, increased gluconeogenesis and DNL are key features of steatosis in HCV patients. Recently it was shown that HCV blocks phosphorylation of forkhead box protein O1 (FOXO1) resulting in enhanced gluconeogenesis and promotion of lipogenesis by increasing the levels of SREBP-1c and fatty acid synthase (FAS)[[94](#_ENREF_94),[96](#_ENREF_96),[105](#_ENREF_105)]. Besides reduced phosphorylation of FOXO1 increased expression of gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6P) was also found to be due to enhanced cyclic AMP responsive element-binding protein phosphorylation linking HCV induced ER stress with increased hepatic glucose output[[106](#_ENREF_106)]. Viral proteins were also found to stimulate transcription of key enzymes of gluconeogenesis and diacylglycerol acyltransferase (DGAT)-1 which catalyses the final step in triglyceride synthesis and affects LD formation. Resulting insulin resistance might further contribute to increased lipogenesis. However, the exact mechanisms have not been fully elucidated in this setting. Furthermore infection with genotype 3 HCV strains has also been found to be associated with reduced levels of phosphatase and tensin homolog (PTEN) which is a negative regulator of insulin/phosphoinositide 3-kinase signalling. Remarkably, interaction of HCV with DDX3, a DEAD box protein, leads to phosphorylation of inhibitor k B kinase α (IKKα) and as a consequence the induction of SREBP-induced lipogenesis and LD formation[[102](#_ENREF_102)]. Beyond quantitative effects, HCV infection was recently shown to alter hepatic metabolic zonation by redistributing fatty acid synthase from perilobular to mid-zone of the lobule[[104](#_ENREF_104)]. Beta-oxidation is also reduced in virus-infected cells due to decreased expression of short-chain acyl-CoA dehydrogenase (SCAD) and medium-chain acyl-CoA dehydrogenase. In vivodata suggest that PPARα expression is also decreased as a consequence of increased suppression by microRNA 27 (miR27) in chronic HCV infection[[99](#_ENREF_99)]. In contrast Tanaka and colleagues[[100](#_ENREF_100)] reported from a mouse model that permanent PPARα activation plays an essential role in development of hepatic steatosis in chronic HCV infection. Remarkably, HCV infection may also directly affect VLDL secretion resulting in intracellular lipid accumulation. Triglyceride content of VLDL particles have been shown to be lower in HCV infected patients[[101](#_ENREF_101)]. In the same study, hepatic lipogenesis was significantly higher and cholesterol synthesis lower in patients with chronic HCV infection when compared to healthy controls[[101](#_ENREF_101)]. Low cholesterol levels have been associated with genotype 3 infection and in contrast to non-responders successful HCV treatment was accompanied by normalization of cholesterol levels[[107](#_ENREF_107)].

**Drug-induced hepatic steatosis**

Several drugs have been found to have the potential to induce usually reversible intrahepatic triglyceride accumulation. These include antimicrobials such as tetracycline, glucocorticoids, tamoxifen, chemotherapeutic agents, methotrexate, anti-arrhythmics such as amiodarone, antiepileptic valproic acid, several antiviral agents, lipid lowering mipomersen and lomitapide and non-steroidal anti-inflammatory drugs such as acetylsalicylic acid, respectively[[108](#_ENREF_108)]. Mechanistically, drug-induced (*e.g.,* valproic acid) diminished mitochondrial β-oxidation of fatty acids leads to excessive reactive oxygen species (ROS) generation und depletion of ATP commonly resulting in development of microvesicular steatosis. Other pathophysiological mechanisms include enhanced cellular uptake of fatty acid due to increased fatty acid translocase expression or increased DNL resulting from elevated expression levels of SREBP1c or decreased AMPK levels. In contrast to the microvesicular steatotic pattern, macrovesicular steatosis is usually considered benign and also often reversible. Detailed mechanisms and outcome have recently been reviewed by Amacher and colleagues[[108](#_ENREF_108)] (Table 2).

**Acute fatty liver of pregnancy**

Acute fatty liver of pregnancy is a rare life-threatening disease in late pregnancy. It is characterized by microvesicular pattern of hepatic steatosis[[109](#_ENREF_109)]. Incidence was estimated as 5/100000 pregnancies in the United Kingdom[[110](#_ENREF_110)]. Mechanistically, fatty liver is due to a defect in mitochondrial β-oxidation. In late pregnancy when the pregnant woman is increasingly dependent on fat as energy source hitherto compensated defect in fatty acid metabolism results in mitochondrial dysfunction[[111](#_ENREF_111),[112](#_ENREF_112)]. Remarkably, risk of acute fatty liver of pregnancy (AFLP) is highly increased when the foetus is homozygous or compound heterozygous for a defect in fatty acid oxidation (FAO)[[113](#_ENREF_113),[114](#_ENREF_114)]. Urgent termination of pregnancy usually leads to significant improvements or normalization of AFLP[[115](#_ENREF_115)] suggesting a pathophysiological role of the placenta in this disease: Mitochondrial dysfunction due to a defect in placental FAO leads to oxidative stress and in parallel accumulation of circulating toxic fatty acid intermediates such as arachidonic acid. Latter have been shown to induce damage, apoptosis and lipid accumulation in hepatocytes[[116](#_ENREF_116)].

**Future Perspectives**

Although knowledge on pathophysiology of fatty liver disease has significantly improved in the past years, treatment options especially of NAFLD are still very limited. Several studies suggest beneficial effects of weight loss on course of NAFLD. Pharmacologically, thiazolidinedione (glitazones) and antioxidative Vitamin E are the most promising therapies today. Novel expectant concepts include activation of SIRT-1 (*e.g.*, reservatrol), which was found to be beneficial in murine models of NAFLD by exerting insulin-sensitizing, antiinflammatory and antioxidative effects[[117](#_ENREF_117),[118](#_ENREF_118)]. In a very recent work, a liver specific LXR inverse agonist significantly reduced hepatic steatosis by reducing de novo lipogenesis[[119](#_ENREF_119)]. The effect of Simtuzumab, which is a humanized antifibrotic monoclonal antibody against Lysyl Oxidase Like Molecule 2 (LOXL2) is currently under investigation in patients with adcanced non-alcoholic fatty liver disease[[120](#_ENREF_120)]. FXR agonists such as obeticholic acid (OCA) are probably the most hopeful and already far advanced therapeutic option under investigation in NAFLD.

**Acknowledgments**

We would like to thank Anna Kirschner, MSc for proofreading and assistance in manuscript preparation.

**References**

1 **Javor ED**, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, Kleiner DE, Gorden P. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. *Hepatology* 2005; **41**: 753-760 [PMID: 15791619 DOI: 10.1002/hep.20672]

2 **Hübscher SG**. Histological assessment of non-alcoholic fatty liver disease. *Histopathology* 2006; **49**: 450-465 [PMID: 17064291 DOI: 10.1111/j.1365-2559.2006.02416.x]

3 **Ekstedt M**, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006; **44**: 865-873 [PMID: 17006923 DOI: 10.1002/hep.21327]

4 **Leandro G**, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology* 2006; **130**: 1636-1642 [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014]

5 **Browning JD**, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; **40**: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]

6 **Leleu H**, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. *J Viral Hepat* 2015; **22**: 376-383 [PMID: 25219291 DOI: 10.1111/jvh.12311]

7 **de Alwis NM**, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. *J Hepatol* 2008; **48** Suppl 1: S104-S112 [PMID: 18304679 DOI: 10.1016/j.jhep.2008.01.009]

8 **Kaser S**, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. *Int J Clin Pract* 2010; **64**: 968-983 [PMID: 20584230 DOI: 10.1111/j.1742-1241.2009.02327.x]

9 **Byrne CD**, Targher G. NAFLD: a multisystem disease. *J Hepatol* 2015; **62**: S47-S64 [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012]

10 **Mittendorfer B**, Magkos F, Fabbrini E, Mohammed BS, Klein S. Relationship between body fat mass and free fatty acid kinetics in men and women. *Obesity (Silver Spring)* 2009; **17**: 1872-1877 [PMID: 19629053 DOI: 10.1038/oby.2009.224]

11 **Pardina E**, Baena-Fustegueras JA, Llamas R, Catalán R, Galard R, Lecube A, Fort JM, Llobera M, Allende H, Vargas V, Peinado-Onsurbe J. Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. *Obes Surg* 2009; **19**: 608-616 [PMID: 19301078 DOI: 10.1007/s11695-009-9827-5]

12 **Nye CK**, Hanson RW, Kalhan SC. Glyceroneogenesis is the dominant pathway for triglyceride glycerol synthesis in vivo in the rat. *J Biol Chem* 2008; **283**: 27565-27574 [PMID: 18662986 DOI: 10.1074/jbc.M804393200]

13 **Doege H**, Grimm D, Falcon A, Tsang B, Storm TA, Xu H, Ortegon AM, Kazantzis M, Kay MA, Stahl A. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. *J Biol Chem* 2008; **283**: 22186-22192 [PMID: 18524776 DOI: 10.1074/jbc.M803510200]

14 **Savage DB**, Murgatroyd PR, Chatterjee VK, O'Rahilly S. Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. *J Clin Endocrinol Metab* 2005; **90**: 1446-1452 [PMID: 15613417 DOI: 10.1210/jc.2004-1494]

15 **Petersen KF**, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. *J Clin Invest* 2002; **109**: 1345-1350 [PMID: 12021250 DOI: 10.1172/jci15001]

16 **Petersen KF**, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proc Natl Acad Sci USA* 2007; **104**: 12587-12594 [PMID: 17640906 DOI: 10.1073/pnas.0705408104]

17 **Petersen KF**, Dufour S, Morino K, Yoo PS, Cline GW, Shulman GI. Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes. *Proc Natl Acad Sci USA* 2012; **109**: 8236-8240 [PMID: 22547801 DOI: 10.1073/pnas.1205675109]

18 **Flannery C**, Dufour S, Rabøl R, Shulman GI, Petersen KF. Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. *Diabetes* 2012; **61**: 2711-2717 [PMID: 22829450 DOI: 10.2337/db12-0206]

19 **Donnelly KL**, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Invest* 2005; **115**: 1343-1351 [PMID: 15864352 DOI: 10.1172/jci23621]

20 **Higuchi N**, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. *Hepatol Res* 2008; **38**: 1122-1129 [PMID: 18684130 DOI: 10.1111/j.1872-034X.2008.00382.x]

21 **Lima-Cabello E**, García-Mediavilla MV, Miquilena-Colina ME, Vargas-Castrillón J, Lozano-Rodríguez T, Fernández-Bermejo M, Olcoz JL, González-Gallego J, García-Monzón C, Sánchez-Campos S. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. *Clin Sci (Lond)* 2011; **120**: 239-250 [PMID: 20929443 DOI: 10.1042/cs20100387]

22 **Browning JD**, Horton JD. Molecular mediators of hepatic steatosis and liver injury. *J Clin Invest* 2004; **114**: 147-152 [PMID: 15254578 DOI: 10.1172/jci22422]

23 **Perry RJ**, Camporez JP, Kursawe R, Titchenell PM, Zhang D, Perry CJ, Jurczak MJ, Abudukadier A, Han MS, Zhang XM, Ruan HB, Yang X, Caprio S, Kaech SM, Sul HS, Birnbaum MJ, Davis RJ, Cline GW, Petersen KF, Shulman GI. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. *Cell* 2015; **160**: 745-758 [PMID: 25662011 DOI: 10.1016/j.cell.2015.01.012]

24 **Delarue J**, Normand S, Couet C, Pachiaudi C, Urbain C, Lamisse F, Riou JP. Effects of free fatty acids on the metabolic response to oral fructose in lean healthy humans. *Int J Obes Relat Metab Disord* 1996; **20**: 130-136 [PMID: 8646249]

25 **Deer J**, Koska J, Ozias M, Reaven P. Dietary models of insulin resistance. *Metabolism* 2015; **64**: 163-171 [PMID: 25441706 DOI: 10.1016/j.metabol.2014.08.013]

26 **Hardie DG**. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. *Endocrinology* 2003; **144**: 5179-5183 [PMID: 12960015 DOI: 10.1210/en.2003-0982]

27 **Nassir F**, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. *Int J Mol Sci* 2014; **15**: 8713-8742 [PMID: 24837835 DOI: 10.3390/ijms15058713]

28 **Koliaki C**, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, Herder C, Carstensen M, Krausch M, Knoefel WT, Schlensak M, Roden M. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. *Cell Metab* 2015; **21**: 739-746 [PMID: 25955209 DOI: 10.1016/j.cmet.2015.04.004]

29 **Mashek DG**, Khan SA, Sathyanarayan A, Ploeger JM, Franklin MP. Hepatic lipid droplet biology: Getting to the root of fatty liver. *Hepatology* 2015; **62**: 964-967 [PMID: 25854913 DOI: 10.1002/hep.27839]

30 **Tan JS**, Seow CJ, Goh VJ, Silver DL. Recent advances in understanding proteins involved in lipid droplet formation, growth and fusion. *J Genet Genomics* 2014; **41**: 251-259 [PMID: 24894352 DOI: 10.1016/j.jgg.2014.03.003]

31 **Ong KT**, Mashek MT, Bu SY, Greenberg AS, Mashek DG. Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. *Hepatology* 2011; **53**: 116-126 [PMID: 20967758 DOI: 10.1002/hep.24006]

32 **Coleman RA**, Mashek DG. Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling. *Chem Rev* 2011; **111**: 6359-6386 [PMID: 21627334 DOI: 10.1021/cr100404w]

33 **Khan SA**, Sathyanarayan A, Mashek MT, Ong KT, Wollaston-Hayden EE, Mashek DG. ATGL-catalyzed lipolysis regulates SIRT1 to control PGC-1α/PPAR-α signaling. *Diabetes* 2015; **64**: 418-426 [PMID: 25614670 DOI: 10.2337/db14-0325]

34 **Singh R**, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism. *Nature* 2009; **458**: 1131-1135 [PMID: 19339967 DOI: 10.1038/nature07976]

35 **Schroeder B**, Schulze RJ, Weller SG, Sletten AC, Casey CA, McNiven MA. The small GTPase Rab7 as a central regulator of hepatocellular lipophagy. *Hepatology* 2015; **61**: 1896-1907 [PMID: 25565581 DOI: 10.1002/hep.27667]

36 **Lian J**, Wei E, Wang SP, Quiroga AD, Li L, Di Pardo A, van der Veen J, Sipione S, Mitchell GA, Lehner R. Liver specific inactivation of carboxylesterase 3/triacylglycerol hydrolase decreases blood lipids without causing severe steatosis in mice. *Hepatology* 2012; **56**: 2154-2162 [PMID: 22707181 DOI: 10.1002/hep.25881]

37 **Li X**, Ye J, Zhou L, Gu W, Fisher EA, Li P. Opposing roles of cell death-inducing DFF45-like effector B and perilipin 2 in controlling hepatic VLDL lipidation. *J Lipid Res* 2012; **53**: 1877-1889 [PMID: 22661308 DOI: 10.1194/jlr.M026591]

38 **Su W**, Wang Y, Jia X, Wu W, Li L, Tian X, Li S, Wang C, Xu H, Cao J, Han Q, Xu S, Chen Y, Zhong Y, Zhang X, Liu P, Gustafsson JÅ, Guan Y. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. *Proc Natl Acad Sci USA* 2014; **111**: 11437-11442 [PMID: 25028495 DOI: 10.1073/pnas.1410741111]

39 **Imai Y**, Varela GM, Jackson MB, Graham MJ, Crooke RM, Ahima RS. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. *Gastroenterology* 2007; **132**: 1947-1954 [PMID: 17484887 DOI: 10.1053/j.gastro.2007.02.046]

40 **Carr RM**, Patel RT, Rao V, Dhir R, Graham MJ, Crooke RM, Ahima RS. Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice. *Am J Physiol Regul Integr Comp Physiol* 2012; **302**: R996-1003 [PMID: 22378776 DOI: 10.1152/ajpregu.00177.2011]

41 **Wang C**, Zhao Y, Gao X, Li L, Yuan Y, Liu F, Zhang L, Wu J, Hu P, Zhang X, Gu Y, Xu Y, Wang Z, Li Z, Zhang H, Ye J. Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis. *Hepatology* 2015; **61**: 870-882 [PMID: 25179419 DOI: 10.1002/hep.27409]

42 **Szendroedi J**, Roden M. Perilipin 5: from fatty liver to hepatic lipodystrophy? *Hepatology* 2015; **61**: 751-753 [PMID: 25420909 DOI: 10.1002/hep.27618]

43 **Romeo S**, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; **40**: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]

44 **Forte TM**, Ryan RO. Apolipoprotein A5: extracellular and intracellular roles in triglyceride metabolism. *Curr Drug Targets* 2015; Epub ahead of print [PMID: 26028042]

45 **Ress C**, Moschen AR, Sausgruber N, Tschoner A, Graziadei I, Weiss H, Schgoer W, Ebenbichler CF, Konrad RJ, Patsch JR, Tilg H, Kaser S. The role of apolipoprotein A5 in non-alcoholic fatty liver disease. *Gut* 2011; **60**: 985-991 [PMID: 21339203 DOI: 10.1136/gut.2010.222224]

46 **Zheng XY**, Zhao SP, Yu BL, Wu CL, Liu L. Apolipoprotein A5 internalized by human adipocytes modulates cellular triglyceride content. *Biol Chem* 2012; **393**: 161-167 [PMID: 22718631 DOI: 10.1515/hsz-2011-0259]

47 **Gao Z**, Zhang J, Kheterpal I, Kennedy N, Davis RJ, Ye J. Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. *J Biol Chem* 2011; **286**: 22227-22234 [PMID: 21540183 DOI: 10.1074/jbc.M111.228874]

48 **Samuel VT**, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *J Biol Chem* 2004; **279**: 32345-32353 [PMID: 15166226 DOI: 10.1074/jbc.M313478200]

49 **Kantartzis K**, Machann J, Schick F, Fritsche A, Häring HU, Stefan N. The impact of liver fat vs visceral fat in determining categories of prediabetes. *Diabetologia* 2010; **53**: 882-889 [PMID: 20099057 DOI: 10.1007/s00125-010-1663-6]

50 **Kumashiro N**, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, Petersen KF, Samuel VT, Shulman GI. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. *Proc Natl Acad Sci USA* 2011; **108**: 16381-16385 [PMID: 21930939 DOI: 10.1073/pnas.1113359108]

51 **Magkos F**, Su X, Bradley D, Fabbrini E, Conte C, Eagon JC, Varela JE, Brunt EM, Patterson BW, Klein S. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. *Gastroenterology* 2012; **142**: 1444-6.e2 [PMID: 22425588 DOI: 10.1053/j.gastro.2012.03.003]

52 **Samuel VT**, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. *J Clin Invest* 2007; **117**: 739-745 [PMID: 17318260 DOI: 10.1172/jci30400]

53 **Dries DR**, Gallegos LL, Newton AC. A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production. *J Biol Chem* 2007; **282**: 826-830 [PMID: 17071619 DOI: 10.1074/jbc.C600268200]

54 **Hotamisligil GS**. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell* 2010; **140**: 900-917 [PMID: 20303879 DOI: 10.1016/j.cell.2010.02.034]

55 **Tilg H**, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. *Trends Endocrinol Metab* 2008; **19**: 371-379 [PMID: 18929493 DOI: 10.1016/j.tem.2008.08.005]

56 **Lipina C**, Hundal HS. Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance. *Diabetologia* 2011; **54**: 1596-1607 [PMID: 21468641 DOI: 10.1007/s00125-011-2127-3]

57 **Liu JD**, Leung KW, Wang CK, Liao LY, Wang CS, Chen PH, Chen CC, Yeh EK. Alcohol-related problems in Taiwan with particular emphasis on alcoholic liver diseases. *Alcohol Clin Exp Res* 1998; **22**: 164S-169S [PMID: 9622397]

58 **Stickel F**, Hoehn B, Schuppan D, Seitz HK. Review article: Nutritional therapy in alcoholic liver disease. *Aliment Pharmacol Ther* 2003; **18**: 357-373 [PMID: 12940921]

59 **Diehl AM**. Alcoholic liver disease: natural history. *Liver Transpl Surg* 1997; **3**: 206-211 [PMID: 9346741]

60 **Bellentani S**, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. *Gut* 1997; **41**: 845-850 [PMID: 9462221]

61 **Mandayam S**, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. *Semin Liver Dis* 2004; **24**: 217-232 [PMID: 15349801 DOI: 10.1055/s-2004-832936]

62 **Seth D**, Haber PS, Syn WK, Diehl AM, Day CP. Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. *J Gastroenterol Hepatol* 2011; **26**: 1089-1105 [PMID: 21545524 DOI: 10.1111/j.1440-1746.2011.06756.x]

63 **Lieber CS**. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. *Adv Pharmacol* 1997; **38**: 601-628 [PMID: 8895826]

64 **Rocco A**, Compare D, Angrisani D, Sanduzzi Zamparelli M, Nardone G. Alcoholic disease: liver and beyond. *World J Gastroenterol* 2014; **20**: 14652-14659 [PMID: 25356028 DOI: 10.3748/wjg.v20.i40.14652]

65 **Grant BF**, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. *Semin Liver Dis* 1988; **8**: 12-25 [PMID: 3283941 DOI: 10.1055/s-2008-1040525]

66 **Day CP**, James OF. Steatohepatitis: a tale of two "hits"? *Gastroenterology* 1998; **114**: 842-845 [PMID: 9547102]

67 . Berg JM, Tymoczko JL, Stryer L: Lipids and cell membranes. In: Biochemistry, fifth edition.New York: W. H. Freeman; Fifth Edition edition 2002: 1050.

68 **You M**, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). *J Biol Chem* 2002; **277**: 29342-29347 [PMID: 12036955 DOI: 10.1074/jbc.M202411200]

69 **Reddy JK**, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. *Annu Rev Nutr* 2001; **21**: 193-230 [PMID: 11375435 DOI: 10.1146/annurev.nutr.21.1.193]

70 **Evans RM**, Barish GD, Wang YX. PPARs and the complex journey to obesity. *Nat Med* 2004; **10**: 355-361 [PMID: 15057233 DOI: 10.1038/nm1025]

71 **Yu S**, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. *Curr Mol Med* 2003; **3**: 561-572 [PMID: 14527087]

72 **Lee GY**, Kim NH, Zhao ZS, Cha BS, Kim YS. Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. *Biochem J* 2004; **378**: 983-990 [PMID: 14641110 DOI: 10.1042/bj20031565]

73 **Nanji AA**, Dannenberg AJ, Jokelainen K, Bass NM. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. *J Pharmacol Exp Ther* 2004; **310**: 417-424 [PMID: 15016835 DOI: 10.1124/jpet.103.064717]

74 **Galli A**, Pinaire J, Fischer M, Dorris R, Crabb DW. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. *J Biol Chem* 2001; **276**: 68-75 [PMID: 11022051 DOI: 10.1074/jbc.M008791200]

75 **Li HH**, Tyburski JB, Wang YW, Strawn S, Moon BH, Kallakury BV, Gonzalez FJ, Fornace AJ. Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor α protects against alcoholic liver disease. *Alcohol Clin Exp Res* 2014; **38**: 1520-1531 [PMID: 24773203 DOI: 10.1111/acer.12424]

76 **Zhong W**, Zhang W, Li Q, Xie G, Sun Q, Sun X, Tan X, Sun X, Jia W, Zhou Z. Pharmacological activation of aldehyde dehydrogenase 2 by Alda-1 reverses alcohol-induced hepatic steatosis and cell death in mice. *J Hepatol* 2015; **62**: 1375-1381 [PMID: 25543082 DOI: 10.1016/j.jhep.2014.12.022]

77 **Guo R**, Xu X, Babcock SA, Zhang Y, Ren J. Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy. *J Hepatol* 2015; **62**: 647-656 [PMID: 25457208 DOI: 10.1016/j.jhep.2014.10.009]

78 **Xu A**, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. *J Clin Invest* 2003; **112**: 91-100 [PMID: 12840063 DOI: 10.1172/jci17797]

79 **Liangpunsakul S**, Wou SE, Zeng Y, Ross RA, Jayaram HN, Crabb DW. Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation. *Am J Physiol Gastrointest Liver Physiol* 2008; **295**: G1173-G1181 [PMID: 18832448 DOI: 10.1152/ajpgi.90349.2008]

80 **García-Ruiz C**, Colell A, Marí M, Morales A, Calvo M, Enrich C, Fernández-Checa JC. Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. *J Clin Invest* 2003; **111**: 197-208 [PMID: 12531875 DOI: 10.1172/jci16010]

81 **Wehr H**, Rodo M, Lieber CS, Baraona E. Acetaldehyde adducts and autoantibodies against VLDL and LDL in alcoholics. *J Lipid Res* 1993; **34**: 1237-1244 [PMID: 8371070]

82 **Carr RM**, Peralta G, Yin X, Ahima RS. Absence of perilipin 2 prevents hepatic steatosis, glucose intolerance and ceramide accumulation in alcohol-fed mice. *PLoS One* 2014; **9**: e97118 [PMID: 24831094 DOI: 10.1371/journal.pone.0097118]

83 **Hu M**, Wang F, Li X, Rogers CQ, Liang X, Finck BN, Mitra MS, Zhang R, Mitchell DA, You M. Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice. *Hepatology* 2012; **55**: 437-446 [PMID: 21953514 DOI: 10.1002/hep.24708]

84 **Yin H**, Hu M, Liang X, Ajmo JM, Li X, Bataller R, Odena G, Stevens SM, You M. Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling and aggravates alcoholic fatty liver. *Gastroenterology* 2014; **146**: 801-811 [PMID: 24262277 DOI: 10.1053/j.gastro.2013.11.008]

85 **Goossens N**, Negro F. Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection. *Rev Recent Clin Trials* 2014; **9**: 204-209 [PMID: 25514907]

86 **Bochud PY**, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. *J Hepatol* 2009; **51**: 655-666 [PMID: 19665246 DOI: 10.1016/j.jhep.2009.05.016]

87 **Bugianesi E**, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. *Hepatology* 2006; **44**: 1648-1655 [PMID: 17133473 DOI: 10.1002/hep.21429]

88 **Fartoux L**, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. *Gut* 2005; **54**: 1003-1008 [PMID: 15951550 DOI: 10.1136/gut.2004.050302]

89 **Bedossa P**, Moucari R, Chelbi E, Asselah T, Paradis V, Vidaud M, Cazals-Hatem D, Boyer N, Valla D, Marcellin P. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. *Hepatology* 2007; **46**: 380-387 [PMID: 17659580 DOI: 10.1002/hep.21711]

90 **Czaja AJ**, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. *J Hepatol* 1998; **29**: 198-206 [PMID: 9722200]

91 **Adinolfi LE**, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 2001; **33**: 1358-1364 [PMID: 11391523 DOI: 10.1053/jhep.2001.24432]

92 **Persico M**, Russo R, Persico E, Svelto M, Spano D, Andolfo I, La Mura V, Capasso M, Tiribelli C, Torella R, Iolascon A. SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. *Clin Chem Lab Med* 2009; **47**: 1217-1225 [PMID: 19803812 DOI: 10.1515/cclm.2009.280]

93 **Filipe A**, McLauchlan J. Hepatitis C virus and lipid droplets: finding a niche. *Trends Mol Med* 2015; **21**: 34-42 [PMID: 25496657 DOI: 10.1016/j.molmed.2014.11.003]

94 **Bernsmeier C**, Calabrese D, Heim MH, Duong HT. Hepatitis C virus dysregulates glucose homeostasis by a dual mechanism involving induction of PGC1α and dephosphorylation of FoxO1. *J Viral Hepat* 2014; **21**: 9-18 [PMID: 24329853 DOI: 10.1111/jvh.12208]

95 **Matsuzaki H**, Daitoku H, Hatta M, Tanaka K, Fukamizu A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. *Proc Natl Acad Sci USA* 2003; **100**: 11285-11290 [PMID: 13679577 DOI: 10.1073/pnas.1934283100]

96 **Banerjee A**, Meyer K, Mazumdar B, Ray RB, Ray R. Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. *J Virol* 2010; **84**: 5936-5946 [PMID: 20357092 DOI: 10.1128/jvi.02344-09]

97 **Parvaiz F**, Manzoor S, Iqbal J, McRae S, Javed F, Ahmed QL, Waris G. Hepatitis C virus nonstructural protein 5A favors upregulation of gluconeogenic and lipogenic gene expression leading towards insulin resistance: a metabolic syndrome. *Arch Virol* 2014; **159**: 1017-1025 [PMID: 24240483 DOI: 10.1007/s00705-013-1892-3]

98 **Dharancy S**, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, Gambiez L, Mathurin P, Paris JC, Schoonjans K, Calmus Y, Pol S, Auwerx J, Desreumaux P. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. *Gastroenterology* 2005; **128**: 334-342 [PMID: 15685545]

99 **Singaravelu R**, Chen R, Lyn RK, Jones DM, O'Hara S, Rouleau Y, Cheng J, Srinivasan P, Nasheri N, Russell RS, Tyrrell DL, Pezacki JP. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. *Hepatology* 2014; **59**: 98-108 [PMID: 23897856 DOI: 10.1002/hep.26634]

100 **Tanaka N**, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. *J Clin Invest* 2008; **118**: 683-694 [PMID: 18188449 DOI: 10.1172/jci33594]

101 **Lambert JE**, Bain VG, Ryan EA, Thomson AB, Clandinin MT. Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. *Hepatology* 2013; **57**: 1697-1704 [PMID: 23417775 DOI: 10.1002/hep.25990]

102 **Li Q**, Pène V, Krishnamurthy S, Cha H, Liang TJ. Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. *Nat Med* 2013; **19**: 722-729 [PMID: 23708292 DOI: 10.1038/nm.3190]

103 **Oshiumi H**, Ikeda M, Matsumoto M, Watanabe A, Takeuchi O, Akira S, Kato N, Shimotohno K, Seya T. Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction. *PLoS One* 2010; **5**: e14258 [PMID: 21170385 DOI: 10.1371/journal.pone.0014258]

104 **Moreau M**, Rivière B, Vegna S, Aoun M, Gard C, Ramos J, Assenat E, Hibner U. Hepatitis C viral proteins perturb metabolic liver zonation. *J Hepatol* 2015; **62**: 278-285 [PMID: 25220251 DOI: 10.1016/j.jhep.2014.09.004]

105 **Bose SK**, Kim H, Meyer K, Wolins N, Davidson NO, Ray R. Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus. *J Virol* 2014; **88**: 4195-4203 [PMID: 24478438 DOI: 10.1128/jvi.03327-13]

106 **Yao W**, Cai H, Li X, Li T, Hu L, Peng T. Endoplasmic reticulum stress links hepatitis C virus RNA replication to wild-type PGC-1α/liver-specific PGC-1α upregulation. *J Virol* 2014; **88**: 8361-8374 [PMID: 24829353 DOI: 10.1128/jvi.01202-14]

107 **Corey KE**, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. *Hepatology* 2009; **50**: 1030-1037 [PMID: 19787818 DOI: 10.1002/hep.23219]

108 **Amacher DE**, Chalasani N. Drug-induced hepatic steatosis. *Semin Liver Dis* 2014; **34**: 205-214 [PMID: 24879984 DOI: 10.1055/s-0034-1375960]

109 **Eapen CE**, Ramakrishna B, Jose R, Loganathan G, Chandy G. Liver failure during pregnancy. *Gut* 2008; **57**: 83 [PMID: 18094203 DOI: 10.1136/gut.2007.143305]

110 **Knight M**, Nelson-Piercy C, Kurinczuk JJ, Spark P, Brocklehurst P. A prospective national study of acute fatty liver of pregnancy in the UK. *Gut* 2008; **57**: 951-956 [PMID: 18332072 DOI: 10.1136/gut.2008.148676]

111 **Goel A**, Jamwal KD, Ramachandran A, Balasubramanian KA, Eapen CE. Pregnancy-related liver disorders. *J Clin Exp Hepatol* 2014; **4**: 151-162 [PMID: 25755551 DOI: 10.1016/j.jceh.2013.03.220]

112 **Kamimura K**, Abe H, Kawai H, Kamimura H, Kobayashi Y, Nomoto M, Aoyagi Y, Terai S. Advances in understanding and treating liver diseases during pregnancy: A review. *World J Gastroenterol* 2015; **21**: 5183-5190 [PMID: 25954092 DOI: 10.3748/wjg.v21.i17.5183]

113 **Ibdah JA**, Bennett MJ, Rinaldo P, Zhao Y, Gibson B, Sims HF, Strauss AW. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. *N Engl J Med* 1999; **340**: 1723-1731 [PMID: 10352164 DOI: 10.1056/nejm199906033402204]

114 **Yang Z**, Yamada J, Zhao Y, Strauss AW, Ibdah JA. Prospective screening for pediatric mitochondrial trifunctional protein defects in pregnancies complicated by liver disease. *JAMA* 2002; **288**: 2163-2166 [PMID: 12413376]

115 **Xiong HF**, Liu JY, Guo LM, Li XW. Acute fatty liver of pregnancy: over six months follow-up study of twenty-five patients. *World J Gastroenterol* 2015; **21**: 1927-1931 [PMID: 25684961 DOI: 10.3748/wjg.v21.i6.1927]

116 **Natarajan SK**, Thangaraj KR, Eapen CE, Ramachandran A, Mukhopadhya A, Mathai M, Seshadri L, Peedikayil A, Ramakrishna B, Balasubramanian KA. Liver injury in acute fatty liver of pregnancy: possible link to placental mitochondrial dysfunction and oxidative stress. *Hepatology* 2010; **51**: 191-200 [PMID: 20034024 DOI: 10.1002/hep.23245]

117 **Colak Y**, Yesil A, Mutlu HH, Caklili OT, Ulasoglu C, Senates E, Takir M, Kostek O, Yilmaz Y, Yilmaz Enc F, Tasan G, Tuncer I. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. *J Gastrointestin Liver Dis* 2014; **23**: 311-319 [PMID: 25267960 DOI: 10.15403/jgld.2014.1121.233.yck]

118 **Xu F**, Li Z, Zheng X, Liu H, Liang H, Xu H, Chen Z, Zeng K, Weng J. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. *Diabetes* 2014; **63**: 3637-3646 [PMID: 24947350 DOI: 10.2337/db14-0263]

119 **Griffett K**, Welch RD, Flaveny CA, Kolar GR, Neuschwander-Tetri BA, Burris TP. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. *Mol Metab* 2015; **4**: 353-357 [PMID: 25830098 DOI: 10.1016/j.molmet.2015.01.009]

120 **Talal A**, Feron-Rigodon M, Madere J, Subramanian G, Bornstein J. 1319 Simutuzumab, an antifibrotic monoclonal antibody against Lysyl Oxidase-Like 2(LOXL2) enzyme, appears safe and well tolerated in patients with liver disease of diverse etiology. J Hepatol 2013; **58** Suppl1: S532 [DOI: 10.1016/S0168-8278(13)61319-7].

121 **Reid AE**. Nonalcoholic steatohepatitis. *Gastroenterology* 2001; **121**: 710-723 [PMID: 11522755]

122 **Ramesh S**, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. *J Hepatol* 2005; **42** Suppl: S2-12 [PMID: 15777569 DOI: 10.1016/j.jhep.2004.11.022]

123 **Fromenty B**. Drug-induced liver injury in obesity. *J Hepatol* 2013; **58**: 824-826 [PMID: 23298629 DOI: 10.1016/j.jhep.2012.12.018]

**P-Reviewer:** Marin JJG, La Mura V **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Overview on potential causes of fatty liver (adapted from[**[**2**](#_ENREF_2)**,**[**121**](#_ENREF_121)**,**[**122**](#_ENREF_122)**])**

|  |  |
| --- | --- |
| **Etiologies of fatty liver disease** | |
| **Frequent causes:** | |
|  | Non-alcoholic fatty liver disease (NALFD) |
|  | Alcoholic fatty liver disease |
|  | Chronic hepatitis C virus infection |
|  | Drug-induced steatosis |
| **Less common or rare causes:** | |
|  | Inborn errors of metabolism (Wilson disease, abetalipoproteinemia, trosinaemia, hypobetalipoproteinemia) |
|  | Lipodystrophy (congenital or acquired) |
|  | Total parenteral nutrition |
|  | Surgical procedures (*e.g.*, biliopancreatic diversion extensive small bowel resection) |

**Table 2 Overview on drug-induced micro- or macrovesicular forms of fatty liver disease (adapted from[**[**108**](#_ENREF_108)**,**[**123**](#_ENREF_123)**])**

|  |  |
| --- | --- |
| **Causes of drug-induced fatty liver disease** | |
| **Predominantly microvesicular pattern:** | |
|  | Tetracyclin |
|  | Valproic acid |
|  | Amiodarone |
|  | Glucocorticoids |
|  | 5-FU |
|  | Margosa oil |
| **Predominantly macrovesicular pattern:** | |
|  | Acetylsalicylic acid (intoxication) |
|  | Tamoxifen |
| **Mixed pattern:** | |
|  | Antiretroviral agents (*e.g.*, didanosine, stavudine) |
|  | Methotrexate |

****

**Figure 1 Pathophysiological aspects of hepatic triglyceride accumulation in Non-alcoholic fatty liver disease.** Both increased uptake of fatty acids due to elevated whole body lipolysis in states of insulin resistance and enhanced fatty acid synthesis are key features of non-alcoholic fatty liver disease. Increased de novo lipogenesis results from enhanced activation of LXR, SREBP-1c and ChREBP in insulin resistance. SREBP-induced activation of ACC2 leads to accumulation of malonyl CoA, which in turn inhibits CPT-1 activity resulting in reduced β-oxidation. In the liver, triglycerides are stored in LDs which are formed within the lipid bilayer of the ER. Stabilization and growth or LDs is dependent on transmembrane proteins, seipin and triglyceride and phospholipid synthetic enzymes which are located on the LD surface.LDs are catabolized *via* ATGL-dependent hydrolysis and β-oxidation of fatty acids, lysosomal lipases and carboxylesterase 3- and CIDEB- mediated repacking of cytosolic LDs in the ER leading to synthesis of VLDL particle. Intermediates of long chain fatty acids (DAG) inhibit insulin signalling further exacerbating hepatic insulin resistance by exerting proinflammatory effects and reducing activation of the insulin receptor. LXRα: Ligand-activated transcription factor α; SREBP1c: Sterol regulating element binding protein 1c; CPT-1: Carnitine palmitoyl transferase 1; LD: Lipid droplet; ATGL: Adipose triglyceride lipase; CIDEB: Cell death inducing DFFA like effector B; DAG: Diacylglycerol.